Intralipid enhances α1-adrenergic receptor-mediated pressor sensitivity

Hypertension

Volumn 32, Issue 4, 1998, Pages 693-698

  Haastrup, Adetola T ^a   Stepniakowski, Konrad T ^a   Goodfriend, Theodore L ^a   Egan, Brent M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Blood pressure; Fatty acids; Phenylephrine; Receptors, adrenergic

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; FATTY ACID; HEPARIN; INTRALIPID; PHENYLEPHRINE; TRIACYLGLYCEROL; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICOAGULANT AGENT; LIPID EMULSION;

ADULT; ARTICLE; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME ANALYSIS; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; OBESITY; PRESSOR RESPONSE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; PRESSORECEPTOR;

ADRENERGIC ALPHA-AGONISTS; ADULT; ANTICOAGULANTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FAT EMULSIONS, INTRAVENOUS; FATTY ACIDS, NONESTERIFIED; FEMALE; HEPARIN; HUMANS; MALE; PHENYLEPHRINE; PRESSORECEPTORS; RECEPTORS, ADRENERGIC, ALPHA; TRIGLYCERIDES;

EID: 0031595271     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.32.4.693     Document Type: Article

References (31)

1. Peiris A, Sothmann M, Hoffmann R, Hennes M, Wilson G, Gustafson A, Kissebah A. Adiposity, fat distribution and cardiovascular risk. Ann Intern Med. 1989;110:867-872.
2. Kaplan NM. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med. 1989;149:1514-1520.
3. Egan BM, Stepniakowski KT. Evidence linking fatty acids, the risk factor cluster, and vascular pathophysiology: implications for the diabetic hypertensive patient. In. Sowers JR, ed. Diabetes and Vascular Disease. Totowa, NJ: Humana Press; 1996:157-172.
4. Stern M, Haffner S. Body fat distribution and hyperinsulinaemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis. 1986;6: 123-129.
5. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416-422.
6. Reaven GM. Pathophysiology of insulin in resistance human disease. Physiol Rev. 1995;75:473-486.
7. Martin ML, Jensen MD. Effects of body fat distribution on regional lipolysis in obesity. J Clin Invest. 1991;88:609-613.
8. Egan B, Panis R, Hinderliter A, Schork N, Julius S. Mechanism of increased α-adrenergic vasoconstriction in human essential hypertension. J Clin Invest. 1987;80:812-817.
9. Davda RK, Stepniakowski KT, Lu G, Ullian ME, Goodfriend TL, Egan BM. Oleic acid inhibits endothelial cell nitric oxide synthase by a PKC-independent mechanism. Hypertension. 1995;26:764-770.
10. Egan BM, Hennes MMI, Stepniakowski KT, O'Shaughnessy IM, Kissebah AH, Goodfriend TL. Obesity hypertension is related more insulin's fatty acid than glucose action. Hypertension. 1996;27:723-728.
11. Stepniakowski KT, Goodfriend TL, Egan BM. Fatty acids enhance vascular α-adrenergic sensitivity. Hypertension. 1995;25:774-778.
12. Grekin RJ, Dumont CJ, Vollmer AP, Watts SW, Webb RC. Mechanisms in the pressor effects of hepatic portal venous fatty acid infusion. Am J Physiol. 1997;273(1 pt 2):R324-R330.
13. Bülow J. Madsen J, Højgaard L. Reversibility of the effects on local circulation of high lipid concentrations in blood. Scand J Clin Lab Invest. 1990;50:291-296.
14. Stepniakowski KT, Sallee FR, Goodfriend TL, Zhang Z, Egan BM. Fatty acids enhance neurovascular reflex responses by effects on α-adrenoceptors. Am J Physiol. 1996;270:R1340-R1346.
15. Hennes MM, O'Shaughnessy IM, Kelly TM, Labelle P, Egan BM, Kissebah AH. Insulin-resistant lipolysis in abdominally obese hypertensives: role of the renin-angiotensin system. Hypertension. 1996;28:120-126.
16. Štolba P, Dobešova Z, Hušek P, Opltova H, Zicha J, Vrana A, Kuneš J. The hypertriglyceridaemic rat as a genetic model of hypertension and diabetes. Life Sci. 1992;51:733-740.
17. Bãnos G, Carvajal K, Cardoso G, Zamora J, Franco M. Vascular reactivity and effect of serum in a rat model of hypertriglyceridaemia and hypertension. Am J Hypertens. 1997;10:379-388.
18. Zambon A, Hashimoto SI, Brunzell JD. Analysis of techniques to obtain plasma for measurement of levels of free fatty acids. J Lipid Res. 1993;34:1021-1028.
19. Hargreaves M, Kiens B, Richter EA. Effects of increased plasma free fatty acid concentrations on muscle metabolism in exercising men. J Appl Physiol. 1991;70:194-201.
20. 61Ni radiochemical assay of free fatty acids in plasma. Clin Chem. 1987;33:176-179.
21. Cabezas MC, deBruin TWA, deValk HW, Shoulders CC, Jansen H, Erkelens DW. Impaired fatty acid metabolism in familial combined hyperlipidemia: a mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest. 1993;92:160-168.
22. Williams RR, Hunt SC, Hopkins PN, Stults BM, Wu LL, Hasstedt SJ, Barlow GK, Stephenson SH, Lalouel J, Kuida H. Familial dyslipidemic hypertension: evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA. 1988;259:3579-3586.
23. Plotnick GD, Corretti MC, Vogel RA. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vaso-activity following a single high-fat meal. JAMA. 1997;278:1682-1686.
24. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest. 1997;100:1230-1239.
25. Mckeen CR, Brigham KL, Bowers RE, Harris TR. Pulmonary vascular effects of fat emulsion infusion in unanesthetized sheep. J Clin Invest. 1978;61:1291-1297.
26. Grekin RJ, Vollmer AP, Sider RS. Pressor effects of portal venous oleate infusion: a proposed mechanism for obesity hypertension. Hypertension. 1995;26:193-198.
27. Wang W, Xu N, Gustafson A. Lipid changes in plasma and blood cells following intravenous 10% fat infusion in man. Pharmacol Toxicol. 1995;77:377-381.
28. Paolisso G, Gambardella A, Amato L, Tortoriello R, D'Amore A, Varricchio M, D'Onofrio F. Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia. 1995;38:1295-1299.
29. Grossman MI, Moeller HC, Palm L. Effect of lipemia and heparin on free fatty acid concentration of serum in humans. Proc Soc Exp Biol Med. 1955;90:106-109.
30. Zicha J, Dobešova Z. Kuneš J. Plasma triglycerides and red cell ion transport in genetically hypertensive rats. Hypertension. 1997;30(pt 2):636-640.
31. Piatti P, Monti LD, Conti M, Baruffaldi L, Galli L, Phan CV, Guazzini B, Pontiroli AE, Pozza G. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes. 1996;45:316-321.